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Abstract: 
The neuronal ceroid lipofuscinoses (NCLs) are mostly seen as diseases affecting the central 
nervous system, but there is accumulating evidence that they have co-morbidities outside 
the brain. One of these co-morbidities is a decline in cardiac function. This is becoming 
increasingly recognised in teenagers and adolescents with juvenile CLN3, but it may also 
occur in individuals with other NCLs. The purpose of this review is to summarise the current 
knowledge of the structural and functional changes found in the hearts of animal models 
and people diagnosed with NCL.  In addition, we present evidence of structural changes that 
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 NCLs have a cardiac co-morbidity, best described for CLN3 
 
 This review summarises cardiac phenotypes in animal models and NCL patients  
 
 The cardiac phenotype is variable and to date not well studied 
 






NCL - Neuronal ceroid lipofuscinoses 
PPT1- Palmitoyl protein thioesterase 1 
TPP1 - tripeptidyl peptidase 1 
ER - endoplasmic reticulum 
SA node - sinoatrial node 
AV node - atrioventricular node  
Ca2+ - Calcium ion 
ECG - electrocardiogram 
KO - knockout 
ASM – autofluorescent storage material 
 
GROD – granular osmophilic deposits 
 
iPSC - induced pluripotent stem cell 
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Main Text:  
Neuronal ceroid lipofuscinoses (NCLs; sometimes referred to as Batten disease) is the 
generic name for a group of debilitating and life-shortening, neurodegenerative diseases 
that involve lysosomal dysfunction and accumulation of cellular storage material (‘ceroid’; 
sometimes called lipofuscin) [1]. Impaired lysosomal function leads to the clinical hallmarks, 
such as progressive loss of vision, behavioural changes, epilepsy, and psychomotor decline, 
seen in NCL patients. The accumulation of storage materials  within cells may also occur, but 
its contribution to cellular pathology is uncertain. NCL diseases are linked to mutations in 13 
different genes, which encode for a diverse range of proteins that impact on lysosomal 
function. These proteins include lysosomal enzymes (e.g. Palmitoyl protein thioesterase 1, 
PPT1 and tripeptidyl peptidase 1, TPP1), transmembrane proteins localised to the lysosomal 
(e.g. CLN3) or endoplasmic reticulum (ER; e.g. CLN6 and CLN8) membranes. Although 
symptoms can arise in adult life, the majority of NCL-causing gene mutations lead to an 
infantile, late infantile or juvenile disease onset, with devastating consequences for patients 
and their families. Mutations in one of the 13 genes give rise to forms of NCL that may have 
both distinctive and common aspects. For example, mutations in PPT1 or TPP1 cause forms 
of NCL denoted CLN1 and CLN2 respectively, which both commonly affect infants in early 
life.  Whereas, mutations in CLN3 lead to similar a similar loss of vision and motor control, 
but the disease typically has a later onset. For most of the NCL diseases, it is not fully clear 
how the altered functions of proteins encoded by the mutated genes lead to the 
development of the specific diseases. Although, there is increasing understand of the 
functions and locations of some of the wild type proteins at the cellular level [2, 3]. NCL is 
the most common form of inherited infantile/juvenile dementia, and considerable effort is 
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Potentially life-extending therapies for NCLs are becoming available ([5]; also reviewed in 
[2]), in particular for those NCLs in which the cellular dysfunctions caused by gene mutations 
are known. For example, CLN1 and CLN2 are due to mutations in enzymes involved in the 
processing of proteins by lysosomes, and hence enzyme replacement therapy could be a 
viable option. Intraventricular enzyme replacement therapy has been approved for CLN2 
disease. The effects of the treatment are encouraging so far, but it is not known what the 
long-term consequences of this treatment will be and natural history studies are underway 
to assess this. Due to the progressive neurodegeneration associated with all forms of NCL, 
the central nervous system has been a primary focus of research and therapeutic strategies. 
However, alterations in the peripheral nervous system and other organs, such as the heart, 
are known and lead to incapacitating co-morbidities [6]. It is therefore important to 
understand the co-morbidities arising outside the CNS in patients with the various NCLs. In 
particular, accumulating evidence suggests that changes in heart function affects NCL 
patients’ quality of life and their levels of activity and mobility. It is plausible that therapies 
developed to treat CNS-related dysfunctions in NCLs may also have benefit for peripheral 
tissues [7, 8].  
 
Whilst it is clear that the heart is affected in NCLs, there are substantial gaps in 
understanding what goes wrong, and in particular why and when. Anecdotal case studies 
from juvenile CLN3 patients reported changes in heart function and accumulation of storage 
material from as early as 1979 [9], and a first systematic review was published in 2011 [10]. 
To date, the majority of co-morbidities associated with the heart were described for juvenile 
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heart relative to other NCL mutations, perhaps because juvenile CLN3 has a later onset than 
the infantile forms. However, the various NCLs progress through similar depreciative 
phases, and it is likely that cardiac pathologies are a feature of all NCLs, and as yet they may 
have been overlooked or not investigated in some instances. To our knowledge, neither the 
causes nor the timescale in which the cardiac pathology develops has been systematically 
studied for the various NCLs. There is an abundance of NCL animal models that recapitulate 
many aspects of the diseases. These models could provide a basis for understanding cardiac 
issues associated with the NCLs, but so far, such models have rarely been used to study the 
changes in structure or function of the heart.  
 
 
Function of the normal heart  
The mammalian heart is a muscular pump that consists of two atrial chambers and two 
ventricular chambers. The atrial chambers are located above the ventricles and receive 
blood coming into the heart from the systemic and pulmonary circulations. Blood passes 
through the atrial chambers into the ventricles, where the major force for blood pumping is 
developed [11]. Each beat f the heart arises from a highly coordinated series of events that 
involves electrical excitation, contraction and electrical/mechanical relaxation; collectively 
these events are referred to as the cardiac cycle [12, 13]. The heart contains cells that 
display automaticity, which is the capacity to generate spontaneous action potentials. The 
sinoatrial node (SA node), a specialised group of cardiomyocytes located in the right atrial 
chamber, is the healthy heart’s principle pacemaker because it has a relatively high intrinsic 
frequency of action potential generation [14]. Other cells within the heart, notably the 
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located towards the lower back aspect of the septum between the right and left atria, can 
act as a secondary pacemaker and trigger action potentials albeit with a lower frequency.  
 
When an action potential is generated by the SA node it rapidly propagates across the right 
and left atrial chambers, thereby causing electrical excitation of the contractile 
cardiomyocytes in the atrial walls that leads to blood being squeezed into the ventricles. 
Under sedentary conditions, the pressure of venous blood return accounts for the majority 
of ventricular blood filling. During periods of increased oxygen demand, such as when 
exercising, the atrial chambers can be stimulated to contract more forcefully and thereby 
contribute significantly to ventricular filling. This increased atrial blood pumping capacity is 
sometimes referred to as atrial kick, and its contribution can decline in certain cardiac 
pathologies such as atrial fibrillation. It takes approximately 30 milliseconds for the action 
potential to propagate across the atrial chambers and reach the AV node, which acts as a 
conduit for the transmission of the electrical signal to the ventricular chambers. On reaching 
the AV node, there is a short pause (~100 milliseconds) in the propagation of the action 
potential to ensure completion of atrial systole and to prevent the transfer of aberrant 
electrical activity such as the spontaneous depolarisations that occur during atrial 
fibrillation. The lower portion of the AV node is designated the bundle of His, which then 
splits into the left and right branches, allowing activation of the left and right ventricles [15]. 
The bundle branches culminate in Purkinje fibres that pass action potentials to groups of 
contractile cardiomyocytes, thereby causing the heart to contract upwards from the 
ventricular base and expel blood in a coordinated manner to the lungs and body. Backflow 
of blood between the atrial and ventricular chambers, or from the pulmonary and aortic 
















An increase in cytosolic calcium ion (Ca2+) concentration is the link between electrical 
excitation of cardiomyocytes and contraction [13, 16, 17]. When a cardiomyocyte is 
depolarised by the arrival of an action potential, voltage-activated Ca2+ channels in the 
sarcolemma (the myocyte cell membrane) are opened, and there is an influx of Ca2+ from 
the extracellular space. This initial surge of Ca2+ is not sufficient to trigger contraction to any 
significant extent, but is amplified by a process of Ca2+-induced Ca2+ release via ryanodine 
receptors (a family of Ca2+-activated, Ca2+ permeable channels) [18] located on the 
sarcoplasmic reticulum (a Ca2+-storing organelle in muscle cells) [19]. The Ca2+ signal arising 
from activation of ryanodine receptors diffuses throughout the cardiomyocyte. Upon 
reaching the contractile actomyosin fibres, Ca2+ binds to troponin C, which consequently 
allows the engagement of actin and myosin so that they can slide past each other and cause 
shortening of the cell [20, 21]. The simultaneous contraction of the millions of 
cardiomyocytes that make up the walls of the heart generates the force for pumping of 
blood. To allow the heart to relax and be ready for the next beat, the mechanical change, 
and the electrical and Ca2+ signals have to recover. Alterations in the conduction of action 
potentials within the heart, or in the excitation or recovery of cardiomyocytes, can lead to 
abnormal and reduced cardiac performance. For example, aberrant Ca2+ signals, which arise 
with cardiomyocytes under various conditions, can prevent cells from responding to 
incoming action potentials [22]. Moreover, aberrant Ca2+ signals, along with numerous 
other factors, can cause the heart to undergo hypertrophic growth [16]. Initially, 
hypertrophy may support cardiac function and support blood pumping, but it can progress 
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electrocardiogram, using electrodes placed on the chest and body. The phases of heart 
depolarisation and repolarisation can be recorded, and any abnormalities in their 
occurrence or timing can be used to diagnose cardiac problems such blocks in the 
conduction of action potentials within the heart. Healthy patients are typical said to be in 
‘sinus rhythm’ where their heart beats at an expected rate (~70 beats per minute) and with 
the anticipated order of electrical events. Arrhythmias occur when heart beats in an 
unexpected manner, which may be too slow (bradycardia), too fast (tachycardia) or 
irregularly. 
 
The volume of blood pumped by the heart depends on the beating frequency (heart rate) 
and stroke volume (the volume of blood pumped by the heart during a cardiac cycle). Both 
factors can be altered by neuronal and hormonal signals. Heart rate is principally controlled 
by the autonomic nervous system, via efferent neurons emanating from the cardiovascular 
regulation centres in the medulla within the brainstem [23]. The medulla integrates 
electrical, chemical and mechanical signals and consequently adjusts heart rate. The 
parasympathetic nervous system, via the vagal nerves, slows heart rate through the release 
of acetylcholine at the SA and AV nodes. In contrast, the sympathetic nervous system 
increases heart rate by releasing epinephrine and norepinephrine at the SA and AV nodes. 
In addition to their chronotropic effects (i.e. rate of heart beating), both the 
parasympathetic and sympathetic nervous systems can impact on inotropy (i.e. the force of 
contraction) by releasing neurotransmitters in the vicinity of contractile cardiomyocytes. 
The overall heart rate and force of contraction is determined by a balance between the 
input from the parasympathetic and sympathetic nervous systems, in addition to effects of 
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itself [24]. Moreover, the heart has its own intrinsic nervous system that send afferent 
signals to the brain that can also impact on heart rate [23]. Interestingly, there are links 
between the cardiac nervous system and cognitive functions [12].   
 
Cardiac phenotypes in NCL animal models 
Animal models available for the various NCLs have been reviewed elsewhere [25-27]. Small 
animal models include murine models, zebrafish and Drosophila [26]. Relatively few studies 
have characterised heart function in these model systems (outlined below and summarised 
in Table 1). Accumulation of storage material (either autofluorescent ceroid or the subunit C 
of the mitochondrial ATPase) was found in all NCL animal models apart from the cathepsin 
D knockout mouse that is used as a model for CLN10 [28] (summarised in Table 1).  
 
Small animal models 
A detailed phenotypic characterisation of the cardiac function (blood pressure, heart rate, 
markers for hypertrophy, electrocardiogram) was published for the CLN3Δex7/8 mouse. The 
only difference observed was a slight increase of the heart weight at 12-19 months of age 
[29]. An enlarged heart was also found in a zebrafish model of CLN3, but no changes in the 
heart’s function were reported [30]. Similarly, a CLN1 mouse model showed no differences 
in electrocardiogram (ECG) parameters at 7 months of age. Analysis of specific markers 
indicated a trend towards hypertrophy, but no significant differences were found. Storage 
material was mostly present in endothelial cells inside the heart and in valve stromal cells, 
and only to a small extent in cardiomyocytes [31]. No reports of changes in the heart 
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Large animal models  
Large animals are considered to be physiologically more relevant to the human pathology 
because of the size of their hearts, similar heart rate and life-span [32]. NCLs occur 
spontaneously in large animals such as dogs and sheep. For some more frequently occurring 
NCLs, breeding stocks have been established and the relevant NCL animal models are 
available (reviewed in [25, 27]). The largest number of NCLs has been described in dogs: CLN 
1, 2, 6, 7, 8, 10 [33-40]. Several ovine models exist for CLN5 and 6 [41], and a bovine model 
for CLN5 [42]. In addition to these, a non-human primate model (macaque) is available for 
CLN7 [43]. The changes in cardiac structure and function reported for these models are 
described below and summarised in Table 1.  
 
Similar to the small animal models, changes in cardiac structure and function were rarely 
studied systematically in the large animal models. After more frequent reports showing a 
cardiac pathology in CLN3 patients, Palmer et al. investigated whether they were also 
present in CLN6 Merino sheep [41], but found neither changes in heart function nor an 
accumulation of storage material. In contrast, pronounced cardiac pathologies were found 
in canine CLN7 and CLN8 models. The English Setter was originally described as model for 
NCLs in 1982 [44], and later confirmed to carry a mutation causing CLN8 [45]. Armstrong et 
al. performed a detailed study of the cardiac pathology on the English Setter in 1986 [46] 
and found that the animals showed sinus arrhythmias, conduction problems and signs of 
left ventricular hypertrophy. The characteristic accumulation of autofluorescent storage 
material (ASM), presence of curvilinear bodies and calcification was found in the Setters’ 












Page 12 of 33 
 
models [35, 36, 43]. The macaques showed bradycardia and abnormal ECGs with prolonged 
P wave width and PR interval, potentially indicating conduction problems  [43], whilst 






















GROD and storage material in hearts from 7 month-old animals, 
mostly in endothelial cells and only to a lesser extent in 
cardiomyocytes. ECGs were used to measure cardiac function 
(filling, ejection fraction, size), but no significant differences 
found. Trend towards hypertrophy. 
[31] 
CLN2 Mouse CLN2-/- mouse shows accumulation of ASM in the heart without 
any gross alteration of the cells’ structure 
[47] 
CLN2 Canine Gene therapy extends survival in a TPP1-/- canine model, at 
which point a cardiac phenotype becomes apparent. Functional 
changes include an increased heart rate, enlarged ventricles 
and a reduced ejection fraction. The heart shows increased 




Slight increase in heart weight, but no changes in heart rate, 
ECG parameters or markers of hypertrophy observed. 
Accumulation of mitochondrial subunit C storage material 
inside the heart.  
[29] 
CLN3 Mouse  Most prominent lac z staining, indicating the CLN3 localisation, 
in the cardiac endothelium, not the myocardium.  
[49] 
CLN3 Zebrafish Elongated heart that lacked pigmented erythrocytes. No 
functional differences wer  reported.  
[30] 
CLN6 Ovine ECGs revealed no functional differences in mid- or late-stage 
Merino sheep. No accumulation of ASM was observed in 
cardiomyocytes, the heart valves, the SA or the AV node.  
[41] 
CLN7 Mouse  
(CLN7 KO) 
Accumulation of mitochondrial ATPase subunit C in hearts from 
CLN7 KO mice. Heart function not studied. 
[50] 
CLN7 Mouse  
(CLN7 KO)  
Accumulation of ASM in cardiomyocytes from CLN7 KO mice. 




Storage material found, without mention of accumulation in the 




ASM accumulation in cardiomyocytes. No report of its 
accumulation in the conduction system or of cardiac deficits in 
the animals. 
[36] 
CLN7 Macaque Accumulation of ASM in the heart. ECGs showed a prolonged P 
wave width and PR interval (potentially indicating delayed 





Six dogs were studied. Sinus arrhythmias, conduction problems, 
QRS-notches and signs of left ventricular hypertrophy were 
found. Accumulation of ASM, presence of curvilinear bodies 
and calcification was found in the hearts. 
[46] 
CLN10 Cathepsin D  
(KO mouse) 
No histological changes were reported for cardiomyocytes.  
Cardiac tissue was enriched with subunit C of the mitochondrial 
F1F0ATPase, but it was not investigated in which cell type or part 




Table 1: Summary of studies using animal NCL models that investigated changes in the 
structure and/or function of the heart. ASM – autofluorescent storage material, GROD – 

















As discussed above, most reports of cardiac dysfunction in NCL human patients have been 
associated with CLN3, which typically has a juvenile onset. A plausible explanation for this 
apparent connection is that cardiac phenotypes may be overlooked in the more rapidly 
degenerating infantile NCL diseases (e.g. CLN1, CLN2 etc) compared to the more slowly 
developing juvenile CLN3. Evidence that supports this hypothesis was provided by a study in 
which CLN2 dogs were treated with gene therapy (injection of adeno-associated virus 
encoding TPP1 into the cerebrospinal fluid) [48] that delayed the disease onset and 
prolonged the animals’ life span [8]. Cardiac function in the treated animals was measured 
at a time when untreated animals would be in the end stage of the disease or have 
deceased (i.e. >10 months of age). At this time, the treated animals had impaired cardiac 
function compared to healthy age-matched animals. They showed an increased heart rate, 
enlarged ventricles with an increased end-systolic volume and a reduced ejection fraction. 
Structural changes included the appearance of ASM (although less than in untreated 
animals), and the occurrence of lesions and fibrosis [48]. Whilst more evidence is required, 
the study by Katz et al. could indicate that cardiac problems may develop in all forms of 
NCLs if there is enough life-span. This may have implications for therapeutic approaches 
that seek to alleviate neuronal aspects of NCLs without addressing deterioration in 
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Cardiac phenotypes in human NCLs   
 
Changes in the heart function of teenagers and adolescents with juvenile CLN3 were 
described in early case studies [9, 53] and in autopsy studies [54]. However, it was not until 
2011 that a systematic clinical investigation of cardiac involvement in juvenile CLN3 was 
reported by clinicians in Denmark [10]. The Danish cross-sectional and follow-up study 
comprised twenty-nine children and adolescents with juvenile CLN3, and showed  
progressive cardiac impairment with repolarisation disturbances, expressed by abnormally 
deeply inverted T waves, ventricular hypertrophy, and sinus node dysfunction ultimately 
leading to a severe bradycardia and/or other conduction abnormalities [10].  The inverted T 
waves were present as early as 14 years of age and were associated with an increased risk 
of death during the 7½ years follow-up period. At increasing age, heart rate and heart rate 
variability, expressed as the vagal index, were significantly reduced, suggesting an age-
dependent bidirectional effect of the heart rate: one through decreasing parasympathetic 
activity on the heart and the other through a direct negative influence on sinus node 
automaticity [10]. Four of seven patients beyond 20 years of age had hypertrophy of the left 
ventricular walls, but the ejection fractions were within normal limits. Recently, consecutive 
follow-up studies of heart rate variability in juvenile CLN3 patients up to their third decade 
of life have been published [55]. The parasympathetic activity decreased significantly with 
increasing age, and beyond 15-20 years of age the parasympathetic activity levels were very 
low, nearly totally abolished, whereas there were no similar age-dependent changes in the 
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A similar longitudinal study is ongoing at the University Medical Center Hamburg-Eppendorf, 
Germany. For this latter study, 42 juvenile CLN3 patients are examined every 6 months as 
part of standard of care follow-up in the NCLs specialty clinic at the University Medical 
Center Hamburg-Eppendorf.  Preliminary results from this ongoing data collection showed 
that more than 60% of patients developed a cardiac pathology. These results are in line with 
the Danish cohort reported by Ostergaard et al. [10]. In both cohorts, ECGs and 
echocardiograms showed various cardiac abnormalities, which became more obvious with 
increasing age of the patients and were present in every individual over the age of 20 years 
in the Danish study. Left ventricular hypertrophy and bradycardia were the most common 
pathologies, found in approximately 20-30% of the patients in each study (Table 2 and 
unpublished personal communication) [10, 56], but no consistent pattern of changes was 
seen. Patients in the German study were typically examined longitudinally starting at 
disease diagnosis, before the onset of changes in ECGs and echocardiograms, which will 
provide insight into the age when the cardiac pathology starts. This was not possible in the 
study conducted in Denmark.   
 
 Denmark 
Total number juvenile CLN3 patients in the 
study 
29  
Patients with any cardiac pathology observed: 
 
15 (52% of all patients) 
Of which,  
 Patients with diagnosed bradycardia: 
 
 
 Patients with diagnosed left ventricular 
hypertrophy: 
 
5 (33% of patients showing a 
cardiac pathology) 
 
4 (27% of patients showing a 
cardiac pathology) 
 
Table 2: Numbers of juvenile CLN3 patients displaying cardiac abnormalities in ECG 
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Where is the cardiac pathology in NCL- the conduction system, the myocytes, or 
everywhere? 
The findings discussed above point to a range of cardiac issues in CLN3, and in particular 
bradycardia and left ventricular hypertrophy. The bradycardia is due to a decrease in 
automaticity of the sinus node most likely because of a lysosomal dysfunction of the 
involved nervous cells. Accumulation of storage material is also seen within the 
atrioventricular node and bundle of His. The hypertrophic growth of the heart is due to a 
lysosomal dysfunction in the contractile cardiomyocytes. What role the accumulation of 
storage material plays is less well known.  Indeed, deposition of ceroid lipopigment has 
been shown to occur extensively in the sinus node, as well as in the atrioventricular node 
and in the bundle of His [54], and to a lesser extent inside the cardiomyocytes [53, 54, 57]. 
However, as pointed out by the animal studies mentioned above, other cell types, such as 
endothelial cells, may also be subjected to phenotypic and functional changes. Fibrosis and 
calcification were frequently observed in histological heart sections from juvenile CLN3 
patients [53, 54].  
 
In ECG recordings, severe bradycardia including sinus arrests for periods as long as 22 
seconds has been demonstrated for a juvenile CLN3 patient [53]. Several case studies exist 
that report pacemaker implantation in individual patients, and some of them showed an 
improvement in their life quality. Following pacemaker-implantation in four Danish patients, 
all individuals expressed that they felt markedly less physically tired, and accordingly, the 
parents noted that their adolescents became more active. In two of the four cases, the 
parents spontaneously said that their youngsters had significantly warmer hands and feet 












Page 18 of 33 
 
CLN3 patient was diagnosed with recurrent episodes of asystoly. This diagnosis happened in 
parallel with a sudden loss of motor and language function. It should be noted that this 
patient had an unsually slowly progressing phenotype prior to this diagnosis despite being 
homozyogus for the most common mutation in the CLN3 gene: a 1 kb deletion.  After 
implantation of a cardiac pacemaker, the patient’s motor and language function rapidly 
improved, resulting in a change of rating from 0 to 1 scoring unit in each of the motor and 
language functions using the Hamburg juvenile NCL score [58]. 
 
Cardiac complications have also been described in CLN1, CLN2 and CLN6 patients. CLN1 
patients had no apparent cardiac problems during their lifetime, but showed a mild dilation 
of the ventricles and accumulation of storage material in a post-mortem analysis [53]. One 
CLN2 patient who had an atypically slow disease progression developed ventricular 
tachycardia and an AV block after the age of 23 years [59]. Two sibling CLN6 patients 
developed cardiac abnormalities of different degrees. The more prominent pathology 
included arrhythmia and conduction blocks. Post-mortem hearts from both patients showed 
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CLN1 Juvenile CLN1 patient with c.287G>A mutation (not mentioned 
whether homo- or heterozygous). No cardiac symptoms 
during the lifetime. During a post-mortem mild dilation of the 
ventricles was found, and accumulation of ASM within 
cardiomyocytes. Cells of the conduction system also showed 
strong accumulation of ASM and deterioration (vacuolisation 
of the cytoplasm, GROD accumulation).  
[53] 
CLN2 Late infantile CLN2 patient with a c.857A>G mutation (heterozygous). 
Normal ECGs at 14 and 20 years of age. Right and left bundle 
blocks and bradycardia observed from the age of 23. Two 
episodes of tachycardia at the age of 23 and 27 and a 
complete AV block, leading to the death at 28 years of age.  
[59] 
CLN3  Juvenile Cardiac hypertrophy and thickened mitral valves observed. 
EM images show curvilinear bodies, fingerprint patterns and 




CLN3 Juvenile Patient homozygous for 1.02 kb deletion with severe 
bradycardia, reduced ejection fraction, repolarisation 
abnormalities and T wave inversion were observed, together 
with left ventricular hypertrophy.   
[62] 
CLN3  Juvenile (n=2) First patient (homozygous for the 1.02 kb deletion) with left 
ventricular hypertrophy and r polarisation problems. Second 
patient (homozygous for the 1.02 kb deletion) with severe 
arrhythmia (bradycardia). Cardiomyocytes from both patients 
showed vacuolisation of the cytoplasm and accumulation of 
ASM. Fibrosis and infiltration of fat was observed in both 
hearts. ASM accumulation was stronger in the conduction 
system than in c rdiomyocytes.   
[53] 
CLN3 Juvenile (n=2) Siblings diagnosed by evidence of vacuolated lymphocytes and 
a typical skin biopsy. Patient 1 with bradycardia and 
ventricular hypertrophy. Periods of sinus arrest, atrial and 
ventricular tachycardia. Patient 2 with shortened PR intervals 
and only mild ventricular hypertrophy. Both patients showed 
accumulation of ASM mostly in the conduction system (SA and 
AV node), and to a lesser extend in the cardiomyocytes.  
[57] 
CLN3  Juvenile, slow 
progression 
(n=2) 
Brothers with CLN3 (homozygous for the p.Gly165Glu 
mutation).  Both patients were diagnosed with sick sinus 




Frequently observed changes were abnormal P waves, 
bradycardia, right bundle or other forms of conduction blocks.  
Cardiomyocytes were slightly hypertrophic and showed the 
most prominent lipopigment accumulation near the nucleus. 
Fibrosis and calcification were found in both, the endocardium 
and the interstitium. Strong accumulation of ASM was found 
in the conduction system.  
[54] 
CLN6 Adult (n=2) 
 
Diagnosed by a skin biopsy with a typical fingerprint of Kufs 
disease, no genetic testing that confirms the diagnosis. 
Severity of cardiac problems different in the 2 patients. AF 
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tachycardia. AF and inverted T waves in the other patient, 
with mild ventricular hypertrophy but no arrhythmia.  
Cardiomyocytes from both patients showed fibrosis, 
accumulation of ASM and curvilinear bodies.  
?  Adult  No genotyping to confirm the type of NCL. Severe loss of 
mitochondrial integrity and cristae structure, appearance of 
inclusions inside mitochondria, GROD and other types of 
storage material inside cardiomyocytes  
[64] 
 
Table 3: Summary of case studies indicating changes in the cardiac structure and/or 





How can we study changes in the cardiac structure and function in NCLs? 
The fact that a cardiac pathology is a co-morbidity in juvenile CLN3 is clear from the patient 
records discussed above. Moreover, animal studies indicate that cardiac defects might 
affect other NCL patients if their lifespan is prolonged by a successful treatment [48]. The 
hope that currently approved and experimental therapies might indeed be able to extend 
patients’ life span is high. However, it is too early for the impact of these recently developed 
treatments to be fully known [2, 5]. Thus, it is becoming critical to understand the causes of 
the cardiac problems in NCLs and to see if they could be ameliorated by early treatment, 
thus improving patients’ quality of life. To better understand the changes occurring in 
patients, a regular non-invasive monitoring of cardiac function would be useful and allow 
clinicians to intervene before changes in heart function cause problems, e.g. by implanting 
cardiac pacemakers to prevent arrhythmia [10]. On the other hand, if we want to 
understand the cellular basis for the changes observed and establish the order in which they 
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iPSC-derived cells offer the possibility to study the effects of NCL-causing mutations on 
cardiomyocytes (and other cell types) in the absence of neuronal input. iPSCs with 
mutations in the CLN1, CLN2, CLN3, CLN5, CLN7, CLN8 and CLN10 genes are available, either 
derived from patients [2, 65-67] or generated via CRISPR technology [68-70]  and can be 
differentiated into several different cell types. Two main problems arise when using iPSC-
derived cardiomyocytes: the resulting cells usually have an immature phenotype, and 
differentiation is difficult, expensive and not possible with every iPSC clone. Adult 
cardiomyocytes are terminally differentiated cells with a precise morphology and 
ultrastructure, and their proper function relies on this differentiation.  The shape and size of 
iPSC-derived cardiomyocytes changes over time in culture, but does not fully recapitulate 
adult cell morphology [71]. Cytoskeletal structure in iPSC-derived cardiomyocytes, 
particularly expression of cardiac troponin isoforms, has been used as a marker of 
cardiomyocyte maturity; demonstrating a shift towards adult structure over time post-
differentiation, but it does fully recapitulate adult cardiomyocytes [72, 73]. Other 
differences are in the number of mitochondria [74] or number of nuclei [71]. As discussed 
above, calcium handling and contraction are highly relevant to cardiomyocyte function and 
disease, but are not fully matured in iPSC-derived cells [75]. Differentiation protocols have 
improved to yield a more matured phenotype through methods such as electrical 
stimulation, 3D culture or co-culture [76, 77]. We are currently optimising the protocols to 
differentiate cardiomyocytes from CLN3 patient-derived iPSCs, to compare their structure 
and function to that seen in cardiomyocytes from the corresponding mouse models. 
 
Mouse models are invaluable to study the time-line in which phenotypic changes occur and 
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progression of juvenile CLN3, the control of heart rhythm by the parasympathetic and 
sympathetic nervous systems is altered [10, 55]. The consequences arising from these 
changes can be observed in animal models (see Table 1), but it can be difficult to decipher 
which cell type is the cause of a particular cardiac pathology. Deposition of storage material 
in the conduction system is likely to be the cause of the observed arrhythmia and disrupted 
propagation of electrical signals (conduction and bundle blocks), whilst the hypertrophy 
could be caused by the deposition of storage material in the cardiomyocytes themselves. 
However, cardiomyocytes will undergo hypertrophic growth in response to a number of 
stimuli and stressors [13]. Changes in contractility, calcium homeostasis or signalling could 
therefore cause hypertrophy independent of ASM accumulation.  
 
Structural Changes in Cardiomyocytes from CLN3Δex7/8 mice 
Using hearts from wild-type (WT) and CLN3Δex7/8 mice, we recently undertook a systematic 
investigation into putative structural changes in cardiomyocytes that might be associated 
with the NCLs. Scanning electron microscopy was used to examine the ultrastructure of the 
cardiomyocytes from the WT and CLN3Δex7/8 mice. Most ventricular cardiomyocytes from 6 
month-old WT and CLN3Δex7/8 animals showed a highly organised structure that would be 
expected of healthy terminally-differentiated cardiac cells, with well aligned myofibres and 
rows of intermyofibrillar mitochondria in-between the myofibres (Figure 1A and B). These 
mitochondria are essential to supply the energy to the working myocardium to keep up the 
regular heartbeat [78]. Sections obtained from 18 months-old WT and CLN3 mice also 
showed cardiomyocytes that were highly organised, similar to those observed with 6 
months-old animals (Figure 1C and D). However, there were obvious regions within the 
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disrupted. Specifically, there were cellular regions with apparent empty spaces between 
mitochondria, and between mitochondria and myofibres (Figure 1C and D). Most cells 
studied previously from CLN3 model animals and from patients showed the presence of 
storage material (summarised in Tables 1 and 3). No storage material was obvious in 
cardiomyocytes from the WT animals. It also did not appear frequently in the 
cardiomyocytes from either 6 or 18 months-old CLN3Δex7/8 mice. When storage material was 
observed, it was found between myofibres (Figure 1Ei, Eii and Eiv) or close to the 
sarcolemma (Figure 1, Eiii). Some large areas of storage material were observed (Figure 1, 
Eiii), but they did not resemble curvilinear or fingerprint bodies, both of which were found 
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Figure 1: Ultrastructure of ventricular cardiomyocytes. Cardiac tissue from WT animals at 6 
(panel A) and 18 months of age (panel B), and tissue from 6 (panel C) and 18 (panel D) 
months-old CLN3Δex7/8 mice. Panel E illustrated examples of storage material from 18 
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ARRIVE guidelines were carried out in accordance with the U.K. Animals (Scientific 
Procedures) Act, 1986. m - mitochondria, dm - deteriorated mitochondria, my - myofibres, * 
cellular regions with apparent empty spaces between mitochondria, and between 

















A growing body of evidence indicates that the deteriorating heart function can be a 
significant co-morbidity in NCL, and that rectifying heart function, even to a modest degree, 
may enable patients to access a better quality of life. At present, the bulk of evidence has 
been linked to juvenile CLN3, although it seems likely that cardiac phenotypes will be 
manifest for all NCL forms. It is possible that NCL-linked cardiac pathologies, especially 
bradycardia, are under-reported because they may be mistaken for other complications 
such as epileptic seizures. To date, the underlying causes of altered cardiac function and the 
time-course of changes have rarely been investigated. Although some cardiac abnormalities, 
such as bradycardia and left ventricular hypertrophy, occur frequently in NCL patients, and 
were found in every patient over the age of 20 a study in Denmark, the combination of 
symptoms that manifest in an individual can vary considerably. It is therefore currently 
difficult to describe a typical cardiac pathology for any of the NCLs. However, due to the 
evidence for progressive cardiac impairment in NCL, it has been recommended that heart 
function is examined at least once per year beyond the age of 18 years [10] so that 
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